Imipramine for cytochrome P450 activity determination: A multiple-species metabolic probe

Toxicology in Vitro

Volumn 13, Issue 4-5, 1999, Pages 537-541

  Bull, S ^a   Catalani, P ^a   Garle, M ^b   Coecke, S ^a   Clothier, R ^b  

^a ECVAM   (Italy)

^b NONE

Author keywords

Cytochrome P450; FMO; Imipramine; Microsomes; Substrate probe

Indexed keywords

CYTOCHROME P450; DESIPRAMINE; DIMETHYLANILINE MONOOXYGENASE; IMIPRAMINE; NORCLOMIPRAMINE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; UNCLASSIFIED DRUG;

CONFERENCE PAPER; CONTROLLED STUDY; DRUG METABOLISM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; LIVER MICROSOME;

EID: 0032839103     PISSN: 08872333     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0887-2333(99)00022-3     Document Type: Conference Paper

References (9)

1. Brosen K., Skjelbo E., Nielsen K.K. Imipramine: A model for P450 research. Methods in Enzymology. 272:1996;177-186.
2. Coutts R.T., Su P., Baker G.B., Daneshtalab M. Metabolism of imipramine in vitro by isozyme CYP2D6 expressed in a human cell line, and observation on metabolite stability. Journal of Chromatography. 615:1993;265-272.
3. Lemoine A., Gautier J.C., Azoulay D., Kiffel L., Belloc C., Guengerich F.P., Maurel P., Beaune P., Leroux J.P. Major pathway of imipramine metabolism is catalysed by cytochromes P450 1A2 and P450 3A4 in human liver. Molecular Pharmacology. 43:1993;827-832.
4. Lemoine A., Johann M., Cresteil T. Evidence for the presence of distinct flavin-monooxygenase in human tissues. Archives of Biochemistry and Biophysics. 276:1990;336-342.
5. Nielsen K.K., Brosen K. High-performance liquid chromatography of imipramine and six metabolites in human plasma and urine. Journal of Chromatography. 612:1993;87-94.
6. Sabourin P.J., Tynes R.E., Irwin I., Delanney L.E., Langston J.W. The FAD-containing monooxygenase of lung and liver tissue from rabbit, mouse and pig. Advances in Experimental and Medical Biology. 197:1986;263-272.
7. Skjelbo E., Brosen K., Hallas J., Gram L.F. The mephenytoin oxidation polymorphism is partially responsible for the N-demethylation of imipramine. Clinical Pharmacology and Therapeutics. 49:1991;18-23.
8. Su P., Coutts R.T., Baker G.B., Daneshtalab M. Analysis of imipramine and three metabolites produced by isozyme CYP2D6 expressed in a human cell line. Xenobiotica. 23:1993;1289-1298.
9. Zeugin T.B., Brosen K., Meyer U.A. Determination of imipramine and seven of its metabolites in human liver microsomes by a high-performance liquid chromatography method. Analytical Biochemistry. 189:1990;99-102.